Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 121 to 130 of 130 entries
Sorted by: Best Match Show Resources per page
Identifying "super responders" in pulmonary arterial hypertension.

Pulmonary circulation

Halliday SJ, Hemnes AR.
PMID: 28597766
Pulm Circ. 2017 Apr-Jun;7(2):300-311. doi: 10.1177/2045893217697708. Epub 2017 May 30.

Pharmacotherapeutic options for pulmonary arterial hypertension (PAH) have increased dramatically in the last two decades and along with this have been substantial improvements in survival. Despite these advances, however, PAH remains a progressive and ultimately fatal disease for most...

Cite
Halliday SJ, Hemnes AR. Identifying "super responders" in pulmonary arterial hypertension. Pulm Circ. 2017;7(2):300-311doi: 10.1177/2045893217697708.
Halliday, S. J., & Hemnes, A. R. (2017). Identifying "super responders" in pulmonary arterial hypertension. Pulmonary circulation, 7(2), 300-311. https://doi.org/10.1177/2045893217697708
Halliday, Stephen J, and Hemnes, Anna R. "Identifying "super responders" in pulmonary arterial hypertension." Pulmonary circulation vol. 7,2 (2017): 300-311. doi: https://doi.org/10.1177/2045893217697708
Halliday SJ, Hemnes AR. Identifying "super responders" in pulmonary arterial hypertension. Pulm Circ. 2017 Apr-Jun;7(2):300-311. doi: 10.1177/2045893217697708. Epub 2017 May 30. PMID: 28597766; PMCID: PMC5467924.
Copy Download .nbib Format: NLM
Central line replacement following infection does not improve reinfection rates in pediatric pulmonary hypertension patients receiving intravenous prostanoid therapy.

Pulmonary circulation

McCarthy EK, Ogawa MT, Hopper RK, Feinstein JA, Gans HA.
PMID: 29309237
Pulm Circ. 2018 Jan-Mar;8(1):2045893218754886. doi: 10.1177/2045893218754886. Epub 2018 Jan 08.

Treatment of pediatric pulmonary hypertension (PH) with IV prostanoids has greatly improved outcomes but requires a central line, posing inherent infection risk. This study examines the types of infections, infection rates, and importantly the effect of line management strategies...

Cite
McCarthy EK, Ogawa MT, Hopper RK, et al. Central line replacement following infection does not improve reinfection rates in pediatric pulmonary hypertension patients receiving intravenous prostanoid therapy. Pulm Circ. 2018;8(1):2045893218754886doi: 10.1177/2045893218754886.
McCarthy, E. K., Ogawa, M. T., Hopper, R. K., Feinstein, J. A., & Gans, H. A. (2018). Central line replacement following infection does not improve reinfection rates in pediatric pulmonary hypertension patients receiving intravenous prostanoid therapy. Pulmonary circulation, 8(1), 2045893218754886. https://doi.org/10.1177/2045893218754886
McCarthy, Elisa K, et al. "Central line replacement following infection does not improve reinfection rates in pediatric pulmonary hypertension patients receiving intravenous prostanoid therapy." Pulmonary circulation vol. 8,1 (2018): 2045893218754886. doi: https://doi.org/10.1177/2045893218754886
McCarthy EK, Ogawa MT, Hopper RK, Feinstein JA, Gans HA. Central line replacement following infection does not improve reinfection rates in pediatric pulmonary hypertension patients receiving intravenous prostanoid therapy. Pulm Circ. 2018 Jan-Mar;8(1):2045893218754886. doi: 10.1177/2045893218754886. Epub 2018 Jan 08. PMID: 29309237; PMCID: PMC5826011.
Copy Download .nbib Format: NLM
Complications associated with peripherally inserted central catheters and Hickman™ in patients with advanced pulmonary hypertension treated with intravenous prostanoids.

Respiratory medicine

Hinojosa W, Cruz A, Cruz-Utrilla A, Cristo Ropero MJ, López-Medrano F, Gómez I, Arribas-Ynsaurriaga F, Escribano-Subias P.
PMID: 34673343
Respir Med. 2021 Oct 19;189:106649. doi: 10.1016/j.rmed.2021.106649. Epub 2021 Oct 19.

BACKGROUND: Epoprostenol requires continuous infusion and may lead to catheter-related complications. Evidence regarding the comparison between peripherally inserted central catheters (PICC) or tunneled central catheters in Pulmonary Hypertension (PH) is scarce. We sought to study the incidence of mechanical...

Cite
Hinojosa W, Cruz A, Cruz-Utrilla A, et al. Complications associated with peripherally inserted central catheters and Hickman™ in patients with advanced pulmonary hypertension treated with intravenous prostanoids. Respir Med. 2021;189:106649doi: 10.1016/j.rmed.2021.106649.
Hinojosa, W., Cruz, A., Cruz-Utrilla, A., Cristo Ropero, M. J., López-Medrano, F., Gómez, I., Arribas-Ynsaurriaga, F., & Escribano-Subias, P. (2021). Complications associated with peripherally inserted central catheters and Hickman™ in patients with advanced pulmonary hypertension treated with intravenous prostanoids. Respiratory medicine, 189106649. https://doi.org/10.1016/j.rmed.2021.106649
Hinojosa, Williams, et al. "Complications associated with peripherally inserted central catheters and Hickman™ in patients with advanced pulmonary hypertension treated with intravenous prostanoids." Respiratory medicine vol. 189 (2021): 106649. doi: https://doi.org/10.1016/j.rmed.2021.106649
Hinojosa W, Cruz A, Cruz-Utrilla A, Cristo Ropero MJ, López-Medrano F, Gómez I, Arribas-Ynsaurriaga F, Escribano-Subias P. Complications associated with peripherally inserted central catheters and Hickman™ in patients with advanced pulmonary hypertension treated with intravenous prostanoids. Respir Med. 2021 Oct 19;189:106649. doi: 10.1016/j.rmed.2021.106649. Epub 2021 Oct 19. PMID: 34673343.
Copy Download .nbib Format: NLM
New strategy to resume and taper epoprostenol after lung transplant for pulmonary hypertension.

General thoracic and cardiovascular surgery

Ohsumi A, Aoyama A, Kinoshita H, Yoneda T, Yamazaki K, Tanaka S, Nakajima D, Ikeda T, Minatoya K, Date H.
PMID: 34978021
Gen Thorac Cardiovasc Surg. 2022 Jan 03; doi: 10.1007/s11748-021-01746-7. Epub 2022 Jan 03.

OBJECTIVE: The perioperative outcome of lung transplantation (LTx) for patients with severe pulmonary hypertension (PH) remains poor due to the occurrence of primary graft dysfunction (PGD) from left ventricular failure. We hypothesized that tapering pretransplant use of epoprostenol rather...

Cite
Ohsumi A, Aoyama A, Kinoshita H, et al. New strategy to resume and taper epoprostenol after lung transplant for pulmonary hypertension. Gen Thorac Cardiovasc Surg. 2022;doi: 10.1007/s11748-021-01746-7.
Ohsumi, A., Aoyama, A., Kinoshita, H., Yoneda, T., Yamazaki, K., Tanaka, S., Nakajima, D., Ikeda, T., Minatoya, K., & Date, H. (2022). New strategy to resume and taper epoprostenol after lung transplant for pulmonary hypertension. General thoracic and cardiovascular surgery, . https://doi.org/10.1007/s11748-021-01746-7
Ohsumi, Akihiro, et al. "New strategy to resume and taper epoprostenol after lung transplant for pulmonary hypertension." General thoracic and cardiovascular surgery vol. (2022). doi: https://doi.org/10.1007/s11748-021-01746-7
Ohsumi A, Aoyama A, Kinoshita H, Yoneda T, Yamazaki K, Tanaka S, Nakajima D, Ikeda T, Minatoya K, Date H. New strategy to resume and taper epoprostenol after lung transplant for pulmonary hypertension. Gen Thorac Cardiovasc Surg. 2022 Jan 03; doi: 10.1007/s11748-021-01746-7. Epub 2022 Jan 03. PMID: 34978021.
Copy Download .nbib Format: NLM
Unexpected Interruptions in the Inhaled Epoprostenol Delivery System: Incidence of Adverse Sequelae and Therapeutic Consequences in Critically Ill Patients.

Critical care explorations

Block JM, Madhok J, Owyang CG, Merriman KR, Ruoss SJ, Rao VK.
PMID: 34671745
Crit Care Explor. 2021 Oct 14;3(10):e0548. doi: 10.1097/CCE.0000000000000548. eCollection 2021 Oct.

OBJECTIVES: Inhaled epoprostenol is a continuously delivered selective pulmonary vasodilator that is used in patients with refractory hypoxemia, right heart failure, and postcardiac surgery pulmonary hypertension. Published data suggest that inhaled epoprostenol administration via vibrating mesh nebulizer systems may...

Cite
Block JM, Madhok J, Owyang CG, et al. Unexpected Interruptions in the Inhaled Epoprostenol Delivery System: Incidence of Adverse Sequelae and Therapeutic Consequences in Critically Ill Patients. Crit Care Explor. 2021;3(10):e0548doi: 10.1097/CCE.0000000000000548.
Block, J. M., Madhok, J., Owyang, C. G., Merriman, K. R., Ruoss, S. J., & Rao, V. K. (2021). Unexpected Interruptions in the Inhaled Epoprostenol Delivery System: Incidence of Adverse Sequelae and Therapeutic Consequences in Critically Ill Patients. Critical care explorations, 3(10), e0548. https://doi.org/10.1097/CCE.0000000000000548
Block, Jason M, et al. "Unexpected Interruptions in the Inhaled Epoprostenol Delivery System: Incidence of Adverse Sequelae and Therapeutic Consequences in Critically Ill Patients." Critical care explorations vol. 3,10 (2021): e0548. doi: https://doi.org/10.1097/CCE.0000000000000548
Block JM, Madhok J, Owyang CG, Merriman KR, Ruoss SJ, Rao VK. Unexpected Interruptions in the Inhaled Epoprostenol Delivery System: Incidence of Adverse Sequelae and Therapeutic Consequences in Critically Ill Patients. Crit Care Explor. 2021 Oct 14;3(10):e0548. doi: 10.1097/CCE.0000000000000548. eCollection 2021 Oct. PMID: 34671745; PMCID: PMC8522871.
Copy Download .nbib Format: NLM
Complications associated with peripherally inserted central catheters and Hickman™ in patients with advanced pulmonary hypertension treated with intravenous prostanoids.

Respiratory medicine

Hinojosa W, Cruz A, Cruz-Utrilla A, Cristo Ropero MJ, López-Medrano F, Gómez I, Arribas-Ynsaurriaga F, Escribano-Subias P.
PMID: 34673343
Respir Med. 2021 Nov-Dec;189:106649. doi: 10.1016/j.rmed.2021.106649. Epub 2021 Oct 19.

BACKGROUND: Epoprostenol requires continuous infusion and may lead to catheter-related complications. Evidence regarding the comparison between peripherally inserted central catheters (PICC) or tunneled central catheters in Pulmonary Hypertension (PH) is scarce. We sought to study the incidence of mechanical...

Cite
Hinojosa W, Cruz A, Cruz-Utrilla A, et al. Complications associated with peripherally inserted central catheters and Hickman™ in patients with advanced pulmonary hypertension treated with intravenous prostanoids. Respir Med. 2021;189:106649doi: 10.1016/j.rmed.2021.106649.
Hinojosa, W., Cruz, A., Cruz-Utrilla, A., Cristo Ropero, M. J., López-Medrano, F., Gómez, I., Arribas-Ynsaurriaga, F., & Escribano-Subias, P. (2021). Complications associated with peripherally inserted central catheters and Hickman™ in patients with advanced pulmonary hypertension treated with intravenous prostanoids. Respiratory medicine, 189106649. https://doi.org/10.1016/j.rmed.2021.106649
Hinojosa, Williams, et al. "Complications associated with peripherally inserted central catheters and Hickman™ in patients with advanced pulmonary hypertension treated with intravenous prostanoids." Respiratory medicine vol. 189 (2021): 106649. doi: https://doi.org/10.1016/j.rmed.2021.106649
Hinojosa W, Cruz A, Cruz-Utrilla A, Cristo Ropero MJ, López-Medrano F, Gómez I, Arribas-Ynsaurriaga F, Escribano-Subias P. Complications associated with peripherally inserted central catheters and Hickman™ in patients with advanced pulmonary hypertension treated with intravenous prostanoids. Respir Med. 2021 Nov-Dec;189:106649. doi: 10.1016/j.rmed.2021.106649. Epub 2021 Oct 19. PMID: 34673343.
Copy Download .nbib Format: NLM
Complications associated with peripherally inserted central catheters and Hickman™ in patients with advanced pulmonary hypertension treated with intravenous prostanoids.

Respiratory medicine

Hinojosa W, Cruz A, Cruz-Utrilla A, Cristo Ropero MJ, López-Medrano F, Gómez I, Arribas-Ynsaurriaga F, Escribano-Subias P.
PMID: 34673343
Respir Med. 2021 Nov-Dec;189:106649. doi: 10.1016/j.rmed.2021.106649. Epub 2021 Oct 19.

BACKGROUND: Epoprostenol requires continuous infusion and may lead to catheter-related complications. Evidence regarding the comparison between peripherally inserted central catheters (PICC) or tunneled central catheters in Pulmonary Hypertension (PH) is scarce. We sought to study the incidence of mechanical...

Cite
Hinojosa W, Cruz A, Cruz-Utrilla A, et al. Complications associated with peripherally inserted central catheters and Hickman™ in patients with advanced pulmonary hypertension treated with intravenous prostanoids. Respir Med. 2021;189:106649doi: 10.1016/j.rmed.2021.106649.
Hinojosa, W., Cruz, A., Cruz-Utrilla, A., Cristo Ropero, M. J., López-Medrano, F., Gómez, I., Arribas-Ynsaurriaga, F., & Escribano-Subias, P. (2021). Complications associated with peripherally inserted central catheters and Hickman™ in patients with advanced pulmonary hypertension treated with intravenous prostanoids. Respiratory medicine, 189106649. https://doi.org/10.1016/j.rmed.2021.106649
Hinojosa, Williams, et al. "Complications associated with peripherally inserted central catheters and Hickman™ in patients with advanced pulmonary hypertension treated with intravenous prostanoids." Respiratory medicine vol. 189 (2021): 106649. doi: https://doi.org/10.1016/j.rmed.2021.106649
Hinojosa W, Cruz A, Cruz-Utrilla A, Cristo Ropero MJ, López-Medrano F, Gómez I, Arribas-Ynsaurriaga F, Escribano-Subias P. Complications associated with peripherally inserted central catheters and Hickman™ in patients with advanced pulmonary hypertension treated with intravenous prostanoids. Respir Med. 2021 Nov-Dec;189:106649. doi: 10.1016/j.rmed.2021.106649. Epub 2021 Oct 19. PMID: 34673343.
Copy Download .nbib Format: NLM
Inhaled prostacyclin analogues in COVID-19 associated acute respiratory distress syndrome: scientific rationale.

The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology

Mulia EPB, Luke K.
PMID: 34529182
Egypt Heart J. 2021 Sep 16;73(1):82. doi: 10.1186/s43044-021-00208-y.

BACKGROUND: COVID-19 associated acute respiratory distress syndrome (CARDS) is a severe form of SARS CoV-2 infection and affects about 15-30% of hospitalized patients with a high mortality rate. Growing research and data suggest several available drugs with appropriate pharmacological...

Cite
Mulia EPB, Luke K. Inhaled prostacyclin analogues in COVID-19 associated acute respiratory distress syndrome: scientific rationale. Egypt Heart J. 2021;73(1):82doi: 10.1186/s43044-021-00208-y.
Mulia, E. P. B., & Luke, K. (2021). Inhaled prostacyclin analogues in COVID-19 associated acute respiratory distress syndrome: scientific rationale. The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology, 73(1), 82. https://doi.org/10.1186/s43044-021-00208-y
Mulia, Eka Prasetya Budi, and Luke, Kevin. "Inhaled prostacyclin analogues in COVID-19 associated acute respiratory distress syndrome: scientific rationale." The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology vol. 73,1 (2021): 82. doi: https://doi.org/10.1186/s43044-021-00208-y
Mulia EPB, Luke K. Inhaled prostacyclin analogues in COVID-19 associated acute respiratory distress syndrome: scientific rationale. Egypt Heart J. 2021 Sep 16;73(1):82. doi: 10.1186/s43044-021-00208-y. PMID: 34529182; PMCID: PMC8443914.
Copy Download .nbib Format: NLM
In-vitro and in-vivo comparisons of high versus low concentrations of inhaled epoprostenol to adult intubated patients.

Respiratory research

Li J, Augustynovich AE, Gurnani PK, Fink JB.
PMID: 34419068
Respir Res. 2021 Aug 21;22(1):231. doi: 10.1186/s12931-021-01827-4.

BACKGROUND: Inhaled epoprostenol (iEPO) has been shown to reduce pulmonary artery pressure and improve oxygenation. iEPO is mainly delivered via a syringe pump with feed tubing connected to a vibrating mesh nebulizer with high or low formulation concentration delivery.METHODS:...

Cite
Li J, Augustynovich AE, Gurnani PK, et al. In-vitro and in-vivo comparisons of high versus low concentrations of inhaled epoprostenol to adult intubated patients. Respir Res. 2021;22(1):231doi: 10.1186/s12931-021-01827-4.
Li, J., Augustynovich, A. E., Gurnani, P. K., & Fink, J. B. (2021). In-vitro and in-vivo comparisons of high versus low concentrations of inhaled epoprostenol to adult intubated patients. Respiratory research, 22(1), 231. https://doi.org/10.1186/s12931-021-01827-4
Li, Jie, et al. "In-vitro and in-vivo comparisons of high versus low concentrations of inhaled epoprostenol to adult intubated patients." Respiratory research vol. 22,1 (2021): 231. doi: https://doi.org/10.1186/s12931-021-01827-4
Li J, Augustynovich AE, Gurnani PK, Fink JB. In-vitro and in-vivo comparisons of high versus low concentrations of inhaled epoprostenol to adult intubated patients. Respir Res. 2021 Aug 21;22(1):231. doi: 10.1186/s12931-021-01827-4. PMID: 34419068; PMCID: PMC8379597.
Copy Download .nbib Format: NLM
Risk factors and treatment of oxygenator high-pressure excursions during cardiopulmonary bypass.

Perfusion

Hjärpe AK, Jeppsson A, Lannemyr L, Lindgren M.
PMID: 34510993
Perfusion. 2021 Sep 11;2676591211043700. doi: 10.1177/02676591211043700. Epub 2021 Sep 11.

INTRODUCTION: A high-pressure excursion (HPE) is a sudden increase in oxygenator inlet pressure during cardiopulmonary bypass (CPB). The aims of this study were to identify factors associated with HPE, to describe a treatment protocol utilizing epoprostenol in severe cases,...

Cite
Hjärpe AK, Jeppsson A, Lannemyr L, et al. Risk factors and treatment of oxygenator high-pressure excursions during cardiopulmonary bypass. Perfusion. 2021;2676591211043700doi: 10.1177/02676591211043700.
Hjärpe, A. K., Jeppsson, A., Lannemyr, L., & Lindgren, M. (2021). Risk factors and treatment of oxygenator high-pressure excursions during cardiopulmonary bypass. Perfusion, 2676591211043700. https://doi.org/10.1177/02676591211043700
Hjärpe, Anders Karl, et al. "Risk factors and treatment of oxygenator high-pressure excursions during cardiopulmonary bypass." Perfusion vol. (2021): 2676591211043700. doi: https://doi.org/10.1177/02676591211043700
Hjärpe AK, Jeppsson A, Lannemyr L, Lindgren M. Risk factors and treatment of oxygenator high-pressure excursions during cardiopulmonary bypass. Perfusion. 2021 Sep 11;2676591211043700. doi: 10.1177/02676591211043700. Epub 2021 Sep 11. PMID: 34510993.
Copy Download .nbib Format: NLM
Showing 121 to 130 of 130 entries